Big pharma, Biotech, Partnering, Pharma

GSK and J&J are pharma partnering for Ebola vaccine

Posted on 23 October 2014

Tags: , ,

GlaxoSmithKline and Johnson & Johnson will become pharma partnering for increasing production of an Ebola vaccine, with an aim to produce at least 1 million doses next year.

So far, there is no proven vaccine for Ebola, but many pharmaceutical companies have been working on experimental drugs that show promise.

J&J has said that it will produce 250,000 doses by May.

 

For further deal information visit Current Agreements (subscription required)

Related

Report: Top 50 Big Pharma Partnering and M&A Deal Trends

Report: Top 50 Big Biotech Partnering and M&A Deal Trends

Browse: Complete Current Partnering report catalog

View: Partnering Scorecard in CP Insight– view top life science partnering deals by value

View: DealMetrics in CP Insight – the latest deal trend infographics for life science deal making

View: CP Insight’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

View: CP Insight’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter – reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter

Print Friendly, PDF & Email

Leave a Reply